JARDIANCE ® PROTECTION *
JARDIANCE ® PROTECTION *
EXPANDED † 1
Start JARDIANCE ® with metformin. No HbA1c requirement. 1
The ONLY SGLT2i indicated to reduce the risk of CV death * 2, 3
†
Simplified PBS access with no HbA1c requirement: 1
• CV Disease, or
• High risk of a CV event ‡, or
• First Nations Australians
* T2D & eCVD indication: in adult patients with T2D and established CV disease( CAD, PAD, MI or stroke) on top of SOC. 2 ‡ Defined as ≥10 % estimated risk in the next 5 years: www. cvdcheck. org. au.
PBS Information: JARDIANCE ®: Authority Required( STREAMLINED). Type 2 Diabetes. Refer to PBS Schedule for full Authority Required Information.
BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE FROM BOEHRINGER INGELHEIM AT WWW. BOEHRINGER-INGELHEIM. COM. AU / PI OR BY SCANNING THE QR CODE.
Use of this medicinal product in paediatric patients aged 10 to 17 years with type 2 diabetes mellitus is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems
JARDIANCE ® safety in T2D: Very common adverse reactions: hypoglycaemia( combination with metformin and an SU; insulin). Common: hypoglycaemia( combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); hypoglycaemia( T2D patients with HF); UTIs; increased urination; vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; volume depletion( T2D patients aged ≥75 years); thirst; pruritis; serum lipids increased; constipation. Overall, the safety profile in children was similar to the safety profile in adults with type 2 diabetes mellitus. Precautions include patients with type 1 diabetes; ketoacidosis; surgery; not recommended to initiate treatment in patients with eGFR < 20 mL / min / 1.73 m 2. No data are available for children with T2D with eGFR < 60 mL / min / 1.73 m 2 and children below 10 years of age. Please refer to the full Jardiance Approved Product Information for information on Contraindications, other Precautions and Adverse Reactions. 2
References: 1. Pharmaceutical Benefits Scheme. Available at: www. pbs. gov. au. Accessed April 2025. 2. JARDIANCE ® Product Information. 3. Therapeutic Goods Administration. Available at: www. tga. gov. au. Accessed April 2025.
Abbreviations: CAD, coronary artery disease; CV, cardiovascular; eCVD, established cardiovascular disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PAD, peripheral artery disease; PBS, Pharmaceutical Benefits Scheme; SGLT2i, sodium-glucose cotransporter 2 inhibitor; SOC, standard of care; T2D, type 2 diabetes.
Boehringer Ingelheim Pty Limited, ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113 Australia. Copyright © 2025. PC-AU-104325. Prepared March 2025. BOEH0736 _ AusDoc.
NEW PBS LISTING 1